LaNova Medicines Announces First Patient Dosed in Phase I Clinical Trial of LM-2417

Shanghai, September 23, 2025 - LaNova Medicines Ltd. announced that the first patient has been successfully enrolled in the Phase I clinical trial of LM-2417, a first-in-class NaPi2b/4-1BB bispecific antibody independently developed by the company. This milestone marks the official entry of this innovative therapy into clinical development.

NaPi2b, encoded by the SLC34A2 gene, is a member of the type II sodium-dependent phosphate transporter family (SLC34) and plays an important role in phosphate homeostasis. Studies have shown that NaPi2b is highly expressed in multiple malignancies, including high-grade serous ovarian cancer, fallopian tube cancer, primary peritoneal cancer, as well as thyroid cancer, breast cancer, and non-squamous non-small cell lung cancer. In contrast, its expression in normal tissues is limited, making NaPi2b a promising therapeutic target. Several companies worldwide are developing drugs against this target, but no NaPi2b-related therapy has yet been approved.

LM-2417 is developed based on LaNova's proprietary conditionally activated 4-1BB platform, enabling dual and specific binding to NaPi2b on tumor cells and 4-1BB on immune cells. This mechanism allows for precise immune activation within the tumor microenvironment, boosting antitumor activity. Unlike traditional 4-1BB agonists, LM-2417 selectively activates the 4-1BB signaling pathway through a NaPi2b-dependent mechanism, which is expected to significantly reduce toxicity associated with non-specific immune activation.

Preclinical studies have shown that LM-2417 not only induces durable antitumor immune memory but also exhibits strong synergy when combined with other immunotherapies. These attributes highlight its potential to become a first-in-class immunotherapy.

This study is an open-label Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of LM-2417, administered as monotherapy or in combination with other anticancer agents, in patients with advanced solid tumors. LaNova will continue to advance the clinical development of LM-2417, striving to bring new immunotherapy options to patients as soon as possible.